Rubicon Research Limited Schedules Q2 FY27 Call for November 5

Rubicon Research Limited has scheduled its Q2 FY27 results announcement and earnings conference call for November 5, 2026, following 51.6% year-on-year revenue growth reported in its Q1 FY27 investor presentation. The board will consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.

What has Rubicon Research announced for Q2 FY27?

Rubicon Research has informed the exchanges that its board meeting is scheduled for November 5, 2026, to consider and approve unaudited standalone and consolidated financial results for Q2 and the first half of FY27. The announcement, made on October 27, covers the period ended September 30, 2026.

The company separately intimated investors on October 28 that it will hold an earnings conference call on November 5 to discuss Q2 FY27 and half-year results. The call is intended to allow management to review the reported performance and discuss the company's stated future strategy. Rubicon Research also disclosed that its trading window was closed from October 1 ahead of the results process.

How did Rubicon Research perform in Q1 FY27?

Rubicon Research's Q1 FY27 investor presentation reported revenue growth of 51.6% year on year. The presentation showed Q1 FY27 revenue of INR 5,343 million and stated that the quarter's figures included the impact of consolidating Arinna after its acquisition.

The company said Arinna contributed revenue of INR 128 million during the quarter, while its contribution to EBITDA was not material. Rubicon Research also reported US dollar revenue of USD 55 million for Q1 FY27, compared with USD 42 million in Q1 FY26, representing 32% year-on-year growth. It attributed a slight sequential decline in US dollar revenue to tactical measures related to gross margins.

What guidance and operating plans has Rubicon Research disclosed?

Rubicon Research said Q2 FY27 was tracking for sequential growth in US dollar revenue, based on its Q1 earnings communication. This is a company outlook statement rather than a reported Q2 financial result, and the November 5 disclosures will provide the formal quarterly figures.

The company raised its FY27 EBITDA margin guidance to at least 23%. It said the guidance takes account of expected costs relating to employee stock-option plans, Arinna integration and growth initiatives. The stated margin target will be a key operating measure for investors assessing the balance between revenue expansion and planned expenditure.

Why does the New Jersey facility matter to Rubicon Research?

Rubicon Research recently acquired a USFDA-approved manufacturing facility in East Brunswick, New Jersey, for USD 2.9 million through a court-supervised competitive bidding process under Section 363 of the US Bankruptcy Code. The company has said it plans to implement its quality systems at the site.

Commercialisation at the New Jersey facility is targeted for calendar year 2027. The asset is therefore not presented as an immediate contributor to the Q2 FY27 result. Its relevance lies in the company's disclosed plan to expand manufacturing capability in the United States, where it already reports revenue in US dollars.

How does the Q2 update fit into Rubicon Research's financial trend?

Rubicon Research reported FY26 revenue of INR 17,540 million, up 37% year on year, according to its annual report. FY26 EBITDA rose 52% to INR 4,002 million, while profit after tax increased 84% to INR 2,467 million. These reported annual figures provide context for the Q1 growth figures and the revised FY27 margin guidance.

For investors, the November 5 announcement is important because it will show whether the company has maintained the sequential US dollar revenue trajectory referenced after Q1. The disclosures may also provide additional detail on Arinna's integration, the New Jersey facility's preparation timeline and progress against the minimum 23% EBITDA margin guidance. No share-price movement or market reaction was provided in the source material.

Conclusion

Rubicon Research's November 5 board meeting and conference call are the next formal events for assessing Q2 and first-half FY27 performance. The company enters the update after reporting 51.6% year-on-year Q1 revenue growth, INR 5,343 million in Q1 revenue and a revised FY27 EBITDA margin target of at least 23%.

Investors will watch the reported Q2 and H1 results, management's discussion of sequential US dollar revenue growth and any update on Arinna consolidation. Progress on quality-system implementation and the calendar year 2027 commercialisation target for the East Brunswick facility will also remain relevant to the company's stated operating plan.